Cellectar Biosciences, Inc.
CLRB evidence brief
What we can confirm
- BioSniper Score:
- 6.1 / 10
- Market Cap:
- $21.8M
- Lead Asset:
- CLR 121125 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for CLRB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · CLRB
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radioconjugates for cancer, with a lead program in Waldenström macroglobulinemia and a confirmatory Phase 3 trial underway.
Key risk: No approved products
BioSniper Score
Based on 5 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 5 clinical trials · 1 catalyst for Cellectar Biosciences, Inc..
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radioconjugates for cancer, with a lead program in Waldenström macroglobulinemia and a confirmatory Phase 3 trial underway.
- Cash and equivalents of $34.0M as of 2026-06-30 [sec].
- Net income of -$6.9M for the six months ended 2026-06-30 [sec].
- Shareholders' equity of $29.9M as of 2026-06-30 [sec].
- Confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia initiated site activation, with NDA submission planned for mid-2027 under FDA Accelerated Approval Program [news · published 2026-08-13].
- Phase 1b trial of CLR 125 in triple negative breast cancer has enrolled and dosed first patients [news · published 2026-08-13].
What works
- Proprietary phospholipid ether drug conjugate (PDC) platform designed to specifically target cancer cells and deliver improved efficacy and safety [sec_mda · as of 2026-03-04].
- Lead program iopofosine I 131 has shown favorable safety profile and preliminary clinical activity in relapsed/refractory multiple myeloma in a peer-reviewed publication [news · published 2026-07-15].
- Confirmatory Phase 3 trial for iopofosine I 131 in Waldenström macroglobulinemia is underway, with NDA submission planned for mid-2027 under FDA Accelerated Approval Program [news · published 2026-08-13].
- Company is exploring a full range of strategic alternatives to advance its platform and pipeline, including mergers, acquisitions, partnerships, and licensing [sec_mda · as of 2025-11-13].
What to weigh
- Company has not yet reported any product revenue and reported a net loss of $6.9M for the six months ended 2026-06-30 [sec].
- All programs are in clinical or preclinical stages; no approved products to date [sec_mda · as of 2026-03-04].
- Reliance on strategic alternatives (e.g., mergers, partnerships) indicates potential challenges in advancing pipeline independently [sec_mda · as of 2025-11-13].
- Competitive landscape for radioconjugates includes multiple large players (e.g., Incyte, Pierre Fabre) in similar indications [pipeline].
From the filings
Quoted directly from source documents.
Company is a late-stage clinical biopharmaceutical company focused on cancer drugs using a proprietary PDC platform.
“We are a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects.”
SEC MD&A · March 4, 2026
Confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia has initiated site activation, with NDA submission planned for mid-2027.
“Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA’s Accelerated Approval Program”
News · August 13, 2026
Phase 1b trial of CLR 125 in triple negative breast cancer has enrolled and dosed first patients.
“Initiated Enrollment and Dosed First Patients in Phase 1b Clinical Trial of CLR 125 in Triple Negative Breast Cancer”
News · August 13, 2026
Company is exploring strategic alternatives including mergers, acquisitions, partnerships, and licensing.
“explore a full range of strategic alternatives to advance our platform and radiopharmaceutical drug development pipeline. Strategic alternatives under consideration may include, but are not limited to mergers, acquisitions, partnerships, joint ventures, licensing arrangements or other strategic transactions.”
SEC MD&A · November 13, 2025
Catalyst timeline
- 2026-12-01 · Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor — This is the planned start date for the confirmatory Phase 3 trial; initiation of site activation has already been announced.
Risks & what to watch (4)›
Key risks
- No approved products — All programs are in clinical or preclinical stages; no approved products to date [sec_mda · as of 2026-03-04].
- Net loss and no revenue — Reported net loss of $6.9M for six months ended 2026-06-30 and no product revenue [sec].
- Reliance on strategic alternatives — Company is exploring mergers, partnerships, etc., indicating potential challenges in independent advancement [sec_mda · as of 2025-11-13].
- Competitive landscape — Multiple large competitors in radioconjugate space for similar indications [pipeline].
What to watch
- Initiation and enrollment progress of the confirmatory Phase 3 trial of iopofosine I 131 in Waldenström macroglobulinemia [news · published 2026-08-13].
- NDA submission for iopofosine I 131 planned for mid-2027 under FDA Accelerated Approval Program [news · published 2026-08-13].
- Phase 1b data from CLR 125 in triple negative breast cancer [news · published 2026-08-13].
- Outcome of strategic alternatives exploration (mergers, partnerships, etc.) [sec_mda · as of 2025-11-13].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run Cellectar Biosciences, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Cellectar Biosciences, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.23 · 0% dilution
Lead: Phase 1
2 candidates
1 upcoming, next in ~48d
2 buys · 0 sells (180d)
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
19
Total value held
$813K
| Holder | Shares | Value |
|---|---|---|
| bleichroeder lp | 100,000 | $254K |
| vanguard capital management llc | 81,884 | $208K |
| geode capital management, llc | 52,778 | $134K |
| riverview capital advisers, llc | 10,384 | $50K |
| sequoia financial advisors, llc | 18,850 | $48K |
| vanguard fiduciary trust co | 16,573 | $42K |
| warberg asset management llc | 13,900 | $35K |
| ubs group ag | 9,647 | $25K |
| blackrock, inc. | 4,745 | $12K |
| tower research capital llc (trc) | 793 | $2K |
Showing top 10 of 19 institutional holders of Cellectar Biosciences, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 0.5%
- Days to cover
- 0.8
- Shares short
- 22,951
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
CLRB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Cellectar Biosciences, Inc.?
Cellectar Biosciences is a late-stage clinical biopharmaceutical company developing targeted radioconjugates for cancer, with a lead program in Waldenström macroglobulinemia and a confirmatory Phase 3 trial underway.
What is Cellectar Biosciences, Inc.'s lead drug candidate?
Cellectar Biosciences, Inc.'s most advanced tracked candidate is CLR 121125 (Phase 1) for Triple negative breast cancer (TNBC).
What is Cellectar Biosciences, Inc.'s next catalyst?
Cellectar Biosciences, Inc.'s next tracked catalyst is a Phase3_Start event — "Phase3_Start: An Open-Label, Multicenter, Randomized, Phase 3 Trial of Iopofosine I 131 Versus Rituximab-Cyclophosphamide-Dexamethasone (R-CD) in Waldenstrom Macroglobulinemia Patients Previously Treated With a Bruton Tyrosine Kinase Inhibitor" — expected December 1, 2026.
Who is the CEO of Cellectar Biosciences, Inc.?
Mr. James V. Caruso is the chief executive officer of Cellectar Biosciences, Inc. (CLRB).
Where is Cellectar Biosciences, Inc. headquartered?
Cellectar Biosciences, Inc. (CLRB) is headquartered in Florham Park, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.